An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials.
Latest Information Update: 23 Jan 2008
Price :
$35 *
At a glance
- Drugs Torcetrapib/atorvastatin (Primary)
- Indications Coronary disorders; Hyperlipidaemia; Hyperlipoproteinaemia type III; Hypertriglyceridaemia; Lipid metabolism disorders
- Focus Adverse reactions
- Sponsors Pfizer
- 03 Jan 2008 Status changed from recruiting to discontinued.
- 07 Jun 2007 New trial record.